Risk factors | Cross tabulations | Resistance classes (odds ratio & 95% CI) | |||||
---|---|---|---|---|---|---|---|
TET | XNL+ | NAL+ | CIP + NAL + XNL+ | XNL+ | NAL+ | CIP + NAL + XNL+ | |
Enrofloxacin | |||||||
 Untreated | 123 | 95 | 71 | 69 |  |  |  |
 Treated | 51 | 19 | 52 | 64 | 0.5 (0.3–0.9) | 1.8 (1.1–2.9) | 2.2 (1.4–3.6) |
Sulfonamide | |||||||
 Untreated | 28 | 34 | 4 | 7 |  |  |  |
 Treated | 146 | 80 | 119 | 126 | 0.5 (0.3–0.8) | 5.7 (1.9–16.7) | 3.5 (1.5–8.2) |
β-lactams | |||||||
 Untreated | 71 | 56 | 24 | 40 |  |  |  |
 Treated | 103 | 58 | 99 | 93 | 0.7 (0.4–1.4) | 2.8 (1.7–4.9) | 1.6 (1.0–2.6) |
No. of treatments | |||||||
 ×1 | 56 | 35 | 15 | 35 |  |  |  |
 0 | 23 | 31 | 4 | 7 | 2.2 (1.1–4.3) | 0.6 (0.2–2.2) | 0.5 (0.2–1.3) |
 ×2 | 58 | 20 | 41 | 34 | 0.6 (0.3–1.1) | 2.6 (1.3–5.3) | 0.9 (0.5–1.7) |
 ×3 | 24 | 19 | 47 | 36 | 1.3 (0.6–2.6) | 7.3 (3.4–15.5) | 2.4 (1.2–4.7) |
 ×4–6 | 13 | 9 | 16 | 21 | 1.1 (0.4–2.9) | 4.6 (1.8–11.6) | 2.6 (1.1–5.8) |
Age (5 categories) | |||||||
 57 - 80d | 63 | 14 | 17 | 14 |  |  |  |
 43 - 56d | 44 | 16 | 36 | 10 | 1.6 (0.7–3.7) | 3.0 (1.5–6.1) | 1.0 (0.1–0.4) |
 29 - 42d | 28 | 11 | 52 | 20 | 1.8 (0.7–4.4) | 6.9 (3.4–13.9) | 3.2 (1.4–7.3) |
 15 - 28d | 15 | 21 | 14 | 57 | 6.3 (2.6–15.2) | 3.5 (1.4–8.5) | 17.1 (7.6–38.5) |
 1 - 14d | 24 | 52 | 4 | 32 | 9.7 (4.6–20.7) | 0.6 (0.2–2.0) | 6.0 (2.7–13.1) |
Age (2 categories) | |||||||
 29 - 80d | 135 | 41 | 105 | 44 |  |  |  |
 1 - 28d | 39 | 73 | 18 | 89 | 6.2 (3.7–10.4) | 0.6 (0.3–1.1) | 7.0 (4.2–11.6) |
Sampling period | |||||||
 Nov 15 – Jan | 97 | 54 | 30 | 64 |  |  |  |
 Sep – Nov 15 | 55 | 34 | 67 | 42 | 1.1 (0.6–1.9) | 3.9 (2.3–6.8) | 1.2 (0.7–1.9) |
 May – Aug | 22 | 26 | 26 | 27 | 2.1 (1.1–4.1) | 3.8 (1.9–7.7) | 1.9 (1.0–3.5) |